C-CBKUVascarta
transdermal delivery, curcumin, linker chemistry
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CBKU
C-CBKUC-CBKUtransdermal delivery, curcumin, linker chemistry
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Vascarta states that it aims to advance and market novel patent-protected treatments for chronic inflammatory diseases by using transdermal drug loading of circulating blood cells for targeted delivery within the vasculature. The company presents this approach as a way to improve therapeutic effectiveness and patient experience, with focus areas including Sickle Cell Disease, Osteoarthritis, Dementia, and Cancer.
SourceVascarta states that curcumin can be made into an effective and safe pain-relief and anti-inflammatory therapy if its usual bioavailability and stability problems are solved through a proprietary topical transdermal system. The company presents its approach as a natural, science-backed alternative to opioids and conventional topicals, claiming that much higher solubility, deeper skin permeation, capillary uptake, and controlled sustained release allow curcumin to reach targets more precisely and provide meaningful relief across conditions such as osteoarthritis, joint pain, and sickle cell crisis.
SourceVascarta presents the belief that curcumin can become a highly effective and safe pain-relief and inflammation-management therapy if its longstanding bioavailability and stability limits are overcome through a transdermal delivery system. The company states that its technology improves curcumin solubility, enables deeper skin permeation, targets capillary uptake, and provides controlled, sustained systemic distribution, making it a natural, personalized alternative for chronic and acute pain without opioid dependency risks.
SourceVascarta states that many drugs, botanicals, and dietary supplements fail to reach their therapeutic potential because poor solubility and bioavailability limit effectiveness. It presents its patented topical/transdermal delivery platform as a way to fundamentally improve bioavailability and maximize therapeutic potential, using curcumin as its first proof point. The company argues that its formulation greatly increases curcumin solubility and skin penetration, enables direct access to capillaries and blood components, and therefore may enhance therapeutic efficacy for pain, inflammation, vascular integrity, red blood cell health, frailty associated with aging, and other unmet medical needs.
Source